Table 3 TTF2 and OS for CA 19-9 response at any point in time during 2nd-line treatment.

From: Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)

 

TTF2 months (95% CI)

p-value

OS months (95% CI)

p-value

CA 19-9 response (decrease from baseline at any time)

≥25%

Without response (n = 62)

1.91 (1.45–2.30)

<0.001

4.80 (3.75–6.11)

<0.001

With response (n = 52)

5.06 (3.91–6.05)

10.87 (8.08–13.70)

Unknown or NA* (n = 32)

4.21 (2.04–8.41)

9.00 (4.17–11.33)

≥50%

Without response (n = 82)

2.14 (1.84–2.83)

<0.001

6.05 (4.27, 7.66)

<0.001

With response (n = 32)

6.05 (4.14–8.94)

10.91 (8.08–16.79)

Unknown or NA* (n = 32)

4.21 (2.04–8.41)

9.00 (4.17–11.33)

  1. NA not applicable.
  2. *CA 19-9 response classified as not applicable in patients with baseline CA 19-9 of ≤30 μ/ml. p-values are for comparison between “without response” and “with response” groups.
Back to article page